Back to top
more

Kenvue Inc. (KVUE)

(Delayed Data from NYSE)

$21.99 USD

21.99
9,859,198

-0.17 (-0.77%)

Updated Oct 7, 2024 04:00 PM ET

After-Market: $21.99 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Consumer Products - Staples

Better trading starts here.

Zacks News

Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?

JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.

Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?

Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

Smart Beta ETF report for SPYD

Kinjel Shah headshot

J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?

We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.

Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?

Style Box ETF report for SDY

Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?

Style Box ETF report for SPYD

Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?

Smart Beta ETF report for SDY

The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly

Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.

Kinjel Shah headshot

J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?

We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.

International Flavors (IFF) Q2 Earnings Top on Higher Volumes

International Flavors (IFF) reports volume growth in high-single digits in second-quarter 2024. The company expects 2024 sales to be in the range of $11.1-$11.3 billion.

Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Kenvue (KVUE) Q2 Earnings and Revenues Beat Estimates

Kenvue (KVUE) delivered earnings and revenue surprises of 14.29% and 1.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for

Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?

Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.

Kinjel Shah headshot

J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs

J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.

Kinjel Shah headshot

J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Kinjel Shah headshot

J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?

A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.

Want Better Returns? Don?t Ignore These 2 Consumer Staples Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Stock Market News for May 8, 2024

Wall Street ended mixed on Tuesday as investors eagerly awaited signals from the Federal Reserve regarding potential interest rate cuts.

Why Kenvue (KVUE) Could Beat Earnings Estimates Again

Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These 2 Consumer Staples Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation

J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.

J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.

J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Company News for Dec 20, 2023

Companies in The News Are: BA, DLAKY, KVUE, INTC, SHEL